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Abstract Flavonoids are important polyphenolic substances
with widespread occurrence in plants and therefore in the human
diet. Although considerable work has been done on the
pharmacology of flavonoids, the understanding of their metabo-
lism is still incomplete. In this work, the in vitro glucuronidation
of the common dietary flavonoids quercetin and kaempferol by
human UDP-glucuronosyltransferase microsomes (UGT-1A9)
was investigated using HPLC and LC^MS. The two flavonoids
were extensively metabolised by this enzyme with four mono-
glucuronides of quercetin and two of kaempferol being detected
after incubation. The presence of a quercetin monoglucuronide in
the urine of a volunteer after consumption of Ginkgo biloba
tablets was demonstrated.
z 2000 Federation of European Biochemical Societies.
Key words: Quercetin; Kaempferol; Glucuronidation;
Liquid chromatography^mass spectrometry;
UDP-glucuronosyltransferase 1A9; Ginkgo biloba
1. Introduction
A large number of biological activities have been associated
with £avonoids, including antiproliferative [1,2], antioxidant
[3,4] and antiviral [5]. Also, there is epidemiological evidence
of an inverse correlation between £avonoid intake and mor-
tality from coronary heart disease [6] and stroke [7]. Central
to the claims for a role of £avonoids in disease prevention,
however, is the extent to which they are absorbed, metabol-
ised and excreted as well as the possible biological activities of
their metabolites. Early studies on £avonoid metabolism have
concentrated on the acid ¢ssion products resulting after mi-
crobiological cleavage at the heterocyclic ring by intestinal
bacteria [8]. However, with the introduction of analytical de-
velopments such as liquid chromatography^mass spectrome-
try (LC^MS) there is growing evidence that glucuronidation is
central to £avonoid metabolism and absorption [9], especially
for the more hydroxylated ones.
Quercetin and kaempferol (Fig. 1) are common dietary £a-
vonoids and are of particular interest as antioxidants since
they possess a 3-hydroxyl group of relatively low oxidation
potential which is oxidised irreversibly thus avoiding redox
cycling [10]. It has been demonstrated that high amounts of
quercetin can be absorbed from onions [11] and that quercetin
conjugates possess antioxidant properties [12]. In a recent
study we showed that only small amounts of free quercetin
and kaempferol could be detected by GC^MS in human urine
from unsupplemented volunteers, but pre-treatment with
L-glucuronidase signi¢cantly increased the levels detected
[13], suggesting the presence of glucuronides of these com-
pounds in urine.
A drawback of the study of xenobiotic glucuronidation has
always been the lack of UDP-glucuronosyltransferase (UGT,
EC 2.4.1.17) selective substrates and inhibitors, which has
made di⁄cult the interpretation of data obtained with human
liver preparations. An alternative that was made possible only
recently is the heterologous expression of UGT encoding
cDNAs that allows the production of single enzyme isoforms
for metabolism studies.
In this study we found that kaempferol and quercetin are
extensively metabolised in vitro by human UGT-1A9 micro-
somes, with four monoglucuronides of quercetin and two of
kaempferol being produced. The characterisation of these me-
tabolites by LC^MS was successfully achieved and the pres-
ence of quercetin conjugates in human urine samples taken
after consumption of Ginkgo biloba tablets (a plant rich in
quercetin and kaempferol £avonoid glycosides) is demon-
strated.
2. Materials and methods
2.1. Chemicals
Quercetin, kaempferol, uridine diphosphoglucuronic acid (UDP-
GluA), 1,1,1-tris-hydroxymethyl ethane, L-glucuronidase (EC
3.2.1.31) and alamethicin were purchased from Sigma-Aldrich Chem-
ical Co. (Poole, Dorset, UK). Solid phase extraction cartridges (Iso-
lute ENV, 500 mg/3 ml) were purchased from Crawford Scienti¢c
(Strathaven, UK). Human UGT-1A9 (EC 2.4.1.17) microsomes from
transfected lymphoblastoid cell lines were obtained from Cambridge
Bioscience (Cambridge, UK). HPLC grade solvents were obtained
from Merck (Poole, Dorset, UK). G. biloba tablets had a stated con-
tent of 28.8 mg of total £avonoid glycosides and were purchased from
Boots (Glasgow, UK).
2.2. In vitro glucuronidation
A 0.5 ml reaction mixture containing 1 mg/ml of microsomal pro-
tein, 4.5 mM UDP-GluA in 100 mM Tris bu¡er pH 7.5 (containing
10 mM MgCl2), 5 Wg/ml of alamethicin and 300 WM of quercetin (or
400 WM of kaempferol) was incubated in a 1.5 ml Eppendorf vial at
37‡C for 2 h. All incubations were carried out by adding ice-cold
microsomal protein to a prewarmed (37‡C) mixture of bu¡er/sub-
strate/UDP-GluA. After initial mixing, incubation mixtures were not
agitated. Blanks, to which no enzyme was added, and controls with-
out cosubstrate (UDP-GluA) were run in parallel. The reaction was
stopped by adding 0.5 ml of methanol. After incubation the samples
were centrifuged at 4000 rpm for 20 min. The supernatant was trans-
ferred into a vial and 20 Wl injected into the HPLC. Enzyme activity
was determined similarly, but ¢nal incubation volume was 100 Wl, and
the incubation time was 3 h 20 min. Activities are expressed here as
the amount of substrate consumed and not of product formed.
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2.3. Time course of metabolite production
Samples of kaempferol (400 WM) or quercetin (300 WM) were in-
cubated as described above. At each time point, an aliquot of 50 Wl of
the incubate was removed and the reaction stopped by adding 50 Wl of
methanol. The samples were centrifuged at 4000 rpm for 20 min and
20 Wl of the supernatant injected. Blank samples (no enzyme added)
were run in parallel.
2.4. Hydrolysis with L-glucuronidase
An aliquot of 50 Wl from sample incubates was taken and the
solvent removed by heating at 70‡C and blowing o¡ with a stream
of nitrogen. To the residue, 1000 units of L-glucuronidase in 50 mM
acetate bu¡er pH 5 were added, in a ¢nal volume of 100 Wl. Samples
were incubated for 2 h at 37‡C. A blank, to which no enzyme was
added, was run in parallel. After incubation the samples were centri-
fuged at 4000 rpm for 20 min and 20 Wl of the supernatant directly
injected into the HPLC.
2.5. HPLC analysis
High performance liquid chromatography was done using a Ther-
moseparation Spectra Series P100 isocratic pump coupled with a
Knauer variable wavelength detector set at 254 nm. Peak detection
and integration was carried out using a Hewlett Packard HP 3395
integrator. Samples were introduced through a rheodyne injector ¢t-
ted with a 20 Wl loop. Separation was achieved using a Phenomenex
Luna C18 column (75U4.6 mm, 3 Wm). The mobile phase consisted of
a mixture of 0.1% tri£uoroacetic acid and methanol (6:4, v/v) and the
£ow rate was 1 ml/min.
2.6. LC^MS
LC^MS experiments were done using a Thermoquest Finnigan Au-
tomass multi LC-GC^MS system. Separation was achieved with a
Phenomenex Luna C18 column (75U4.6 mm, 3 Wm). Samples (20
Wl) were injected using a Finnigan Spectra System AS 3000 autosam-
pler and introduced at a £ow rate of 0.8 ml/min into the quadrupole
mass spectrometer without splitting. The interface was operated in
negative ion electrospray mode, with a cone voltage of 345 V. The
drying gas temperature was set at 450‡C. UV detection was carried
out using a Finnigan Spectra System UV 6000 LP photodiode array
detector to facilitate peak assignment. Mobile phase consisted of (A)
0.1% acetic acid and (B) methanol. Quercetin metabolites were sepa-
rated using a linear gradient from 40 to 70% B in 20 min while
kaempferol samples were analysed with a gradient from 40 to 88%
B in 20 min.
Fig. 1. Chemical structure of quercetin and kaempferol.
Fig. 2. A: Representative HPLC chromatograms of sample incubates containing 300 WM of quercetin (left) or 400 WM of kaempferol (right)
with UGT-1A9 microsomes. Insets are blank incubates. B: HPLC chromatograms of aliquots taken from A after treatment with 1000 units of
L-glucuronidase.
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2.7. Collection and preparation of urine samples
A urine sample from a human volunteer with no dietary restrictions
was taken 4 h after the ingestion of two tablets of G. biloba. The urine
sample was kept in a freezer (at 320‡C) until analysis. For LC^MS
analysis a urine aliquot was centrifuged (10 000Ug, 5 min) and 5 ml of
the supernatant was acidi¢ed with 1 ml of 0.3 M hydrochloric acid.
Then, 4.8 ml of the acidi¢ed urine was extracted using Isolute ENV
solid phase extraction cartridges (500 mg/3 ml). The cartridges were
conditioned by sequentially passing 4.0 ml of HPLC grade methanol
and 2.0 ml of 0.05 M hydrochloric acid using a vacuum manifold that
gave a £ow rate of ca. 3.5 ml/min. After applying the sample, the
cartridge was dried and then eluted with 3U1.0 ml of methanol.
The solvent was blown o¡ under a stream of nitrogen and the residue
redissolved in 0.5 ml of methanol. The sample was ¢ltered using a
nylon syringe ¢lter (0.45 Wm) prior to injection into the LC^MS.
2.8. Statistics
Values are expressed as mean þ S.D. except when otherwise speci-
¢ed. Activities were compared using unpaired two sample t-test.
3. Results and discussion
Fig. 2A shows the HPLC chromatograms of samples con-
taining 300 WM of quercetin or 400 WM of kaempferol after
incubation with 1 mg/ml of UGT-1A9 microsomal protein for
200 min. Four metabolites of quercetin (Q1^Q4) and two of
kaempferol (K1 and K2) are clearly identi¢ed and all of them
were completely hydrolysed by treatment with L-glucuroni-
dase (Fig. 2B).
The time courses of metabolite accumulation for quercetin
and kaempferol (Fig. 3A,B, respectively) were similar and
linear with time, with no latency period. The use of alamethi-
cin in the incubation medium did not have any measurable
e¡ect on the activity of the enzyme towards the substrates.
This is in contrast with claims from the supplier (Gentest,
Massachusetts) which reports a two-fold increase on the ac-
tivity of UGT-1A9 microsomes towards 7-hydroxy-4-tri£uo-
romethylcoumarin with alamethicin.
Under similar conditions, the enzyme metabolised kaemp-
ferol and quercetin to a similar extent: 55.12 þ 0.45% and
51.93 þ 1.00% (n = 4) respectively. The extent of metabolism
was a¡ected by aliquoting the incubation medium, so that
the values reported here are from experiments in which the
substrates were left undisturbed for the whole incubation pe-
riod (200 min). Thus, when multiple aliquots were taken (as in
the time course experiments, see Fig. 3) the metabolism was
comparatively reduced. The activity of UGT-1A9 was slightly
but consistently (P = 0.0001, n = 4) higher towards kaempferol
in comparison with quercetin (1083.38 þ 3.20 and
843.95 þ 3.20 pmol/min/mg protein respectively, n = 4).
The mobile phase conditions had to be adjusted to carry
out LC^MS analysis in the negative ion mode since tri£uoro-
acetic acid inhibited the formation of negative ions by the
glucuronide metabolites. LC^MS analysis of the incubates
(Fig. 4A,B) revealed that all metabolites consisted of mono-
glucuronides of the corresponding aglycones. In general the
conjugates produced strong molecular ions (m/z 478 [M31]3
and m/z 462 [M31]3 for quercetin and kaempferol respec-
tively) under the conditions used. Also, diagnostic ions corre-
sponding to the quercetin and kaempferol aglycones (m/z 301
and m/z 285 respectively) formed by the loss of a glucuronic
acid moiety [M3177]3 were observed and it was indeed pos-
sible to increase the intensity of these ions by increasing the
cone voltage. Adduct ions resulting from addition of acetic
acid (60 amu) and methanol (32 amu) were also observed
(Table 1).
The analysis of a urine sample taken from a human volun-
teer 4 h after consumption of two tablets of G. biloba revealed
Fig. 3. Time course of metabolite accumulation in the glucuronida-
tion of 300 WM quercetin (A) and 400 WM of kaempferol (B) by hu-
man UGT-1A9 microsomes as determined by HPLC. Each point is
the mean þ S.E.M. of four experiments.
Table 1
Summary of spectral data for quercetin, kaempferol and their metabolites
Compound Relevant ions in ES mass spectrum UV band II
maximum (nm)
UV band I
maximum (nm)
Shifts in relation to
aglyconea (nm)
Quercetin 301b [M31]3 254 370
Metabolite Q1 478b [M31]3, 301 [M3177]3 254 370
Metabolite Q2 478b [M31]3, 301 [M3177]3 256 354 316 (band I)
Metabolite Q3 478b [M31]3, 301 [M3177]3 256 366 34 (band I)
Metabolite Q4 510b [M+MeOH]3, 478 [M31]3, 301 [M3177]3 254 368
Kaempferol 285b [M31]3 256 364
Metabolite K1 522b [M+AcOH]3, 462 [M31]3, 285 [M3177]3 256 366
Metabolite K2 522 [M+AcOH]3, 462b [M31]3, 285 [M3177]3 258 344 322 (band I)
aShifts of less than 3 nm were not considered signi¢cant.
bBase ions.
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a peak with the same mass and retention time of one of the
quercetin glucuronides produced in vitro (Q2) (Fig. 5).
The human UDP-glucuronosyltransferase UGT-1A9 [14] is
known to glucuronidate several bulky phenols including some
£avonoids, and is probably one key enzyme in the metabolism
of xenobiotic compounds [15]. This enzyme isoform is known
to be expressed in human liver [16] and oesophagus [17]
although little is known about other possible extrahepatic
sites, such as intestine. The microsomes used here are from
a lymphoblast cell line (AHH-1 TK=3) transfected with hu-
man liver UGT-1A9 cDNA by an episomal expression system.
Glucuronidation is probably the main route for absorption
and metabolism of £avonoids, specially the more hydroxy-
lated ones, such as quercetin and kaempferol [9]. Indeed, it
was demonstrated that the intestinal mucosa can glucuroni-
date £avonoid aglycones before absorption [18]. It thus seems
reasonable to say that UGT-1A9 can potentially play a role in
the absorption as well as in the metabolism of £avonoid agly-
cones. Indeed, tissue-speci¢c extrahepatic expression of UDP-
glucuronosyltransferases is thought to be part of a complex
regulation of xenobiotic metabolism [17].
In this study it was not possible to determine the position at
which glucuronidation occurs, but since all conjugates had
di¡erent retention times we conclude that quercetin has to
form at least one conjugate in which one of its hydroxyls
from the catechol group is conjugated. Conjugation of the
catechol system has been shown to lead to a decrease in the
radical scavenging properties of 3P,4P-dihydroxylated £avo-
noids [3]. The large hypsochromic shifts of band I on the
absorption spectra of metabolites K2 and Q2 suggest that
these metabolites are the ones in which the glucuronic acid
moiety is attached to the 3- position (see Table 1) since this
position is much more acidic than the other positions and thus
will be appreciably ionised in very dilute acetic acid.
It has recently been suggested that urinary and plasma levels
of quercetin and kaempferol re£ect short-term £avonoid in-
take and that the fraction of quercetin excreted in urine is only
a small fraction of the amount ingested [19]. The determina-
tion of quercetin and kaempferol glucuronides in urine and
plasma by LC^MS should thus accurately re£ect £avonoid
intake. Our results suggest that glucuronidation is indeed the
main metabolic pathway for £avonoid metabolism and that
UGT-1A9 plays a major role in £avonoid glucuronidation.
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Fig. 4. A: LC^MS analysis of incubation samples of 300 WM quercetin (left) and 400 WM kaempferol (right). The traces are extracted ion pro-
¢les (m/z 460^461 for kaempferol and m/z 477^478 for quercetin) of a single linear scan. B: Typical negative ion electrospray mass spectrum of
quercetin (left) and kaempferol (right) glucuronides.
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